Clinical trial
Rituximab in the Treatment of Graves' Disease
NCT00150111 · Odense University Hospital, Other · Completed
Key facts
| NCT number | NCT00150111 |
|---|---|
| Title | Rituximab in the Treatment of Graves' Disease |
| Official title | B Cell Depletion With the Anti-CD20 Monoclonal Antibody Rituximab in the Treatment of Graves' Disease |
| Lead sponsor | Odense University Hospital, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Graves´ Disease, Thyroid Associated Ophthalmopathy |
| Intervention type | Biological, Drug |
| Interventions | Methimazole, Rituximab, Immunization with various vaccines |
| Enrollment | 20 |
| Start date | Jun 1, 2003 |
| Completion | Oct 1, 2006 |
| First posted | Sep 8, 2005 |
| Last update posted | Oct 6, 2006 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: